Korea, China, Japan Register Patents as Fifth After Europe
Attend Europe's Largest Diabetes Conference 'EASD 2023'
Dongwoon Anatech has laid the foundation for entering the global market by obtaining the fifth patent for 'D-SaLife.'
Dongwoon Anatech announced on the 11th that it has completed the registration of the Indian patent for its self-developed saliva glucose diagnostic device, D-SaLife. This is the fifth patent registration following South Korea in 2018, Japan, China, and Europe (37 countries).
According to the United Nations World Population Report, India is the most populous country in the world. In April, it surpassed China to become the world's number one populous country with 1.4 billion people.
It is estimated that 110 million people, or 11.4% of the population, suffer from diabetes. The number of people in the prediabetes stage is also estimated to be 136 million, or 15.3% of the total population. This means that one in ten people has diabetes.
Through patent registration, Dongwoon Anatech plans to actively supply D-SaLife in India in the future to establish a safe and convenient glucose diagnostic device market.
Dongwoon Anatech attended the '59th European Association for the Study of Diabetes (EASD 2023)' held in Hamburg, Germany, from the 2nd for five days to introduce D-SaLife. The European Association for the Study of Diabetes (EASD) is one of the world's largest academic organizations in the field of diabetes, alongside the American Diabetes Association (ADA).
This was the second participation following 'EASD 2022' held last year in Stockholm, Sweden. The exploratory clinical trial research results on D-SaLife conducted at Nowon Eulji University Hospital were selected as a published paper, attracting attention from global companies.
Dongwoon Anatech introduced the results of the second exploratory clinical trial conducted at the Catholic University Seoul St. Mary's Hospital and showcased a prototype of D-SaLife at the exhibition booth, drawing attention. In particular, Professor Seunghwan Lee, head of the clinical research in endocrinology, attended to help understand the medical and statistical significance and potential of D-SaLife, gaining notable interest.
More than 150 healthcare professionals visited the site, exchanging various opinions on product development status, approval status, launch plans, and other topics related to commercialization and global business.
Discussions on global business were held again with Menarini, an Italy-based multinational pharmaceutical distributor. They also agreed to foster further relations with Sinocare, China's largest blood glucose measurement medical device company, regarding entry into the Chinese market and business. Dongwoon Anatech plans to reflect these in its overseas business expansion.
Dongwoon Anatech CEO Dongchul Kim said, "Registering the D-SaLife patent in the Indian market, which accounts for a large portion of the global diabetes market, is highly valuable," adding, "Attending the European EASD is also part of our efforts to enter advanced overseas markets, and we will continue to establish a foundation for global commercialization."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
